Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) Shares Outstanding (Diluted Average) (2016 - 2025)

Dare Bioscience's Shares Outstanding (Diluted Average) history spans 8 years, with the latest figure at $12.8 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 49.45% year-over-year to $12.8 million; the TTM value through Sep 2025 reached $12.8 million, up 49.45%, while the annual FY2021 figure was $61.2 million, 103.23% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $12.8 million in Q3 2025 per DARE's latest filing, up from $8.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $85.5 million in Q1 2023 to a low of $7.2 million in Q2 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $39.2 million, with a median of $28.6 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 134.45% in 2021, then tumbled 91.51% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $61.2 million in 2021, then surged by 38.7% to $84.8 million in 2022, then crashed by 91.05% to $7.6 million in 2023, then increased by 12.48% to $8.5 million in 2024, then soared by 49.45% to $12.8 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Shares Outstanding (Diluted Average) are $12.8 million (Q3 2025), $8.9 million (Q2 2025), and $8.8 million (Q1 2025).